<h2>事件背景和近期股价表现</h2>
<p>启迪医疗（Inspire Medical Systems，INSP）股票在经历了一段时间的低回报后引起了关注，过去一年股价下跌了 70.19%，年初至今下跌了 47.71%。</p>
<p>这些变动使得公司的估值约为 15.8 亿美元，股价收于 48.25 美元。这促使投资者重新评估这家阻塞性睡眠呼吸暂停专业公司的定价情况。</p>
<p>请查看我们对启迪医疗的最新分析。</p>
<p>这 12% 的单日股价下跌标志着过去一年表现疲软，短期股价回报和长期股东总回报均为负。这表明市场情绪已经降温，投资者正在重新评估风险状况。</p>
<p>如果您希望超越此次抛售，并想了解资本在医疗技术领域的流向，扫描其他与睡眠和治疗相关的医疗项目可能会很有帮助。一个选择是使用专注于医疗保健的人工智能股票筛选器，例如 34 只医疗保健 AI 股票。</p>
<p>在经历如此大幅的股价下跌和约 15.8 亿美元的市场价值后，关键问题是启迪医疗是否低于其内在价值交易，或者该股票是否已经反映了未来增长的预期。</p>
<h2>最受欢迎的叙述：39.2% 低估</h2>
<p>启迪医疗最后收盘价为 48.25 美元，而叙述中的公允价值为 79.42 美元，目前的设置反映了该框架与股价之间的巨大差距。</p>
<blockquote>
<p><em>最近在将中心转向启迪 V 下一代系统的过程中出现的延迟，包括较慢的入驻、延迟的 SleepSync 实施和医疗保险账单更新，都是暂时性问题；随着这些障碍的解决（医疗保险账单现已生效，大多数中心预计在第三季度末完成入驻），程序量和收入增长预计将在 2026 年重新加速，因为被压抑的需求将得到释放。</em></p>
</blockquote>
<p><em>阅读完整叙述。</em></p>
<p>想了解为什么较慢的盈利路径仍然支撑更高的公允价值吗？该叙述依赖于稳定的收入增长、韧性的利润率和未来几年的高倍数盈利。</p>
<p><strong>结果：公允价值为 79.42 美元（低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，更高的公允价值观点仍面临真实考验，包括启迪 V 的推广速度较慢和可能的报销变化，这可能会对收入和盈利假设造成压力。</p>
<p>了解启迪医疗叙述的关键风险。</p>
<h2>下一步</h2>
<p>鉴于这里的情绪混合，迅速行动并根据数据测试看涨和谨慎的观点是明智的。要了解目前推动公司乐观情绪的因素，请查看其 3 个关键回报。</p>
<h2>寻找更多投资想法？</h2>
<p>如果启迪医疗在您的关注名单上，不要止步于此；现在扩大您的观察名单，以免错过下一个机会。</p>
<ul>
<li>通过扫描当前筛选出的 48 只高质量低估股票，锁定潜在的价值机会。</li>
<li>通过关注 71 只低风险得分的韧性股票，增强您的下行保护。</li>
<li>通过研究筛选器中包含的 25 只高质量未被发现的宝藏公司，抢占先机。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新：AI 股票筛选器和警报</strong></h3>
<p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
<p>• 分红强劲的公司（收益率 3% 以上）</p>
<p>• 内部人士买入的低估小盘股</p>
<p>• 高增长的科技和 AI 公司</p>
<p>或者从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

启迪医疗

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>启迪医疗系统（INSP）经历了显著的股价下跌，过去一年下跌了 70.19%，年初至今下跌了 47.71%，导致市场估值约为 15.8 亿美元。该股票收盘价为 48.25 美元，远低于其估计的公允价值 79.42 美元。尽管面临近期挑战，包括下一代系统的推出延迟，分析师认为该公司可能被低估，随着市场条件的改善，收入增长的潜力依然存在。投资者被鼓励探索医疗行业的其他机会</p>

<h2>Event context and recent share performance</h2>
<div class="lb-trans"><h2>事件背景和近期股价表现</h2>
</div><p>Inspire Medical Systems (INSP) stock has drawn attention after an extended period of weak returns, including a 70.19% decline over the past year and a 47.71% decline year to date.</p>
<div class="lb-trans"><p>启迪医疗（Inspire Medical Systems，INSP）股票在经历了一段时间的低回报后引起了关注，过去一年股价下跌了 70.19%，年初至今下跌了 47.71%。</p>
</div><p>Those moves leave the company valued at about US$1.58b, with shares closing at US$48.25. This has prompted investors to reassess how the obstructive sleep apnea specialist is currently being priced.</p>
<div class="lb-trans"><p>这些变动使得公司的估值约为 15.8 亿美元，股价收于 48.25 美元。这促使投资者重新评估这家阻塞性睡眠呼吸暂停专业公司的定价情况。</p>
</div><p>See our latest analysis for Inspire Medical Systems.</p>
<div class="lb-trans"><p>请查看我们对启迪医疗的最新分析。</p>
</div><p>That 12% one day share price decline caps a weak run over the past year, with both short term share price returns and longer term total shareholder returns firmly negative. This suggests sentiment has cooled and investors are reassessing the risk profile.</p>
<div class="lb-trans"><p>这 12% 的单日股价下跌标志着过去一年表现疲软，短期股价回报和长期股东总回报均为负。这表明市场情绪已经降温，投资者正在重新评估风险状况。</p>
</div><p>If you are looking beyond this sell off and want to see where capital is flowing in healthcare technologies, it could be useful to scan other sleep and treatment related plays in the medical space. One option is to use a focused healthcare AI stock screener such as 34 healthcare AI stocks.</p>
<div class="lb-trans"><p>如果您希望超越此次抛售，并想了解资本在医疗技术领域的流向，扫描其他与睡眠和治疗相关的医疗项目可能会很有帮助。一个选择是使用专注于医疗保健的人工智能股票筛选器，例如 34 只医疗保健 AI 股票。</p>
</div><p>After such steep share price declines and a market value of about US$1.58b, the key question now is whether Inspire Medical Systems is trading below its underlying worth or if the stock already reflects expectations for any future growth.</p>
<div class="lb-trans"><p>在经历如此大幅的股价下跌和约 15.8 亿美元的市场价值后，关键问题是启迪医疗是否低于其内在价值交易，或者该股票是否已经反映了未来增长的预期。</p>
</div><h2>Most Popular Narrative: 39.2% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：39.2% 低估</h2>
</div><p>With Inspire Medical Systems last closing at $48.25 against a narrative fair value of $79.42, the current setup reflects a wide gap between that framework and the share price.</p>
<div class="lb-trans"><p>启迪医疗最后收盘价为 48.25 美元，而叙述中的公允价值为 79.42 美元，目前的设置反映了该框架与股价之间的巨大差距。</p>
</div><blockquote>
<p><em>The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>最近在将中心转向启迪 V 下一代系统的过程中出现的延迟，包括较慢的入驻、延迟的 SleepSync 实施和医疗保险账单更新，都是暂时性问题；随着这些障碍的解决（医疗保险账单现已生效，大多数中心预计在第三季度末完成入驻），程序量和收入增长预计将在 2026 年重新加速，因为被压抑的需求将得到释放。</em></p>
</blockquote>
</div><p><em>Read the complete narrative.</em></p>
<div class="lb-trans"><p><em>阅读完整叙述。</em></p>
</div><p>Want to understand why a slower earnings path still underpins that higher fair value? The narrative leans on measured revenue growth, resilient margins and a premium earnings multiple years out.</p>
<div class="lb-trans"><p>想了解为什么较慢的盈利路径仍然支撑更高的公允价值吗？该叙述依赖于稳定的收入增长、韧性的利润率和未来几年的高倍数盈利。</p>
</div><p><strong>Result: Fair Value of $79.42 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 79.42 美元（低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, that higher fair value view still faces real tests, including a slower Inspire V rollout and potential shifts in reimbursement that could strain revenue and earnings assumptions.</p>
<div class="lb-trans"><p>然而，更高的公允价值观点仍面临真实考验，包括启迪 V 的推广速度较慢和可能的报销变化，这可能会对收入和盈利假设造成压力。</p>
</div><p>Find out about the key risks to this Inspire Medical Systems narrative.</p>
<div class="lb-trans"><p>了解启迪医疗叙述的关键风险。</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>Given that the sentiment here is mixed, it makes sense to move quickly and test the bullish and cautious points against the data yourself. To see what is currently driving optimism around the company, review its 3 key rewards.</p>
<div class="lb-trans"><p>鉴于这里的情绪混合，迅速行动并根据数据测试看涨和谨慎的观点是明智的。要了解目前推动公司乐观情绪的因素，请查看其 3 个关键回报。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If Inspire Medical Systems is on your radar, do not stop there; broaden your watchlist now so you are not late to the next opportunity.</p>
<div class="lb-trans"><p>如果启迪医疗在您的关注名单上，不要止步于此；现在扩大您的观察名单，以免错过下一个机会。</p>
</div><ul>
<li>Zero in on potential value opportunities by scanning companies that currently screen as 48 high quality undervalued stocks.</li>
<li>Strengthen your downside protection by focusing on businesses filtered through the 71 resilient stocks with low risk scores.</li>
<li>Get ahead of the crowd by researching companies highlighted in the screener containing 25 high quality undiscovered gems.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描当前筛选出的 48 只高质量低估股票，锁定潜在的价值机会。</li>
<li>通过关注 71 只低风险得分的韧性股票，增强您的下行保护。</li>
<li>通过研究筛选器中包含的 25 只高质量未被发现的宝藏公司，抢占先机。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票筛选器和警报</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士买入的低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

在启迪医疗系统（INSP）经历长期股价疲软后评估其估值